Regenxbio Inc. (RGNX) Q4 2018 Earnings Conference Call Transcript
Image source: The Motley Fool.
Regenxbio Inc. (NASDAQ: RGNX)
Q4 2018 Earnings Conference Call
Feb. 27, 2019, 4:30 p.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good afternoon, and welcome to the REGENXBIO Fourth Quarter and Full Year 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we'll conduct a question-and-answer session and instructions will be given at that time. As a reminder, this conference call is being recorded.
I would now like to turn the call over to Mr. Patrick Christmas, Senior Vice President and General Counsel for REGENXBIO. You may begin.
Patrick J. Christmas -- Senior Vice President & General Counsel
Good afternoon, and thank you for joining us.
With us today are Ken Mills, REGENXBIO's President and Chief Executive Officer; and Vit Vasista, our Chief Financial Officer. Earlier this afternoon REGENXBIO released financial and operating results for the three months and full year ended December 31st, 2018. The press release reporting our financial results is available on our website at www.regenxbio.com.
Today's conference call will include forward-looking statements regarding our financial outlook, in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the Risk Factors and the Management's Discussion and Analysis section of REGENXBIO's quarterly (ph) report on Form 10-K for the year ended December 31st, 2018, which is on file with the Securities and Exchange Commission and available on the SEC's website. Any information we provide on this conference call is provided only as of the date of this call, February 27th, 2019, and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise.
Please be advised that today's call is being recorded and webcast. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the Company. Actual results may differ materially.
I would now like to turn the call over to Ken Mills, President and Chief Executive Officer of REGENXBIO. Ken?
Ken Mills -- President and Chief Executive Officer
Thank you, Patrick. Good afternoon, everyone, and thanks for joining us.
On today's conference call we'll provide a recap of our recent progress and update on our product candidates and financial results for the fourth quarter and full year ended 2018. We will also review anticipated upcoming milestones for REGENXBIO and then open the call to questions.
At REGENXBIO, our mission is to improve lives through the curative potential of gene therapy based on our proprietary NAV Technology Platform. Our AAV gene therapy product candidates are designed to deliver genes to cells to address genetic defects or enable cells in the body to produce therapeutic proteins that are intended to impact disease. Through a single administration, our AAV gene therapy product candidates are designed to provide long-lasting effects, potentially significantly altering the course of disease. We believe gene therapy treatments can transform the lives of those facing serious and life threatening diseases, and we aim to progress our research with these patients in mind.
Our proprietary NAV Technology Platform, which leverages the curative potential of gene therapy consists of over 100 novel adeno-associated viral vectors or AAV vectors including AAV7, AAV8, AAV9 and AAVrh10. Our vectors are the results of research efforts aimed at discovering and developing safer and more effective gene therapy vehicles then earlier generation AAV vectors.
Our NAV Technology Platform has significant differentiating attributes as compared to earlier generation AAV vectors: higher expression and increased durability, broad and novel tissue selectivity, reduced immune response and improved manufacturability. Our goal is to utilize these vectors to enable the development of single administration therapies that deliver genes to cells to address genetic defects or that enable cells in the body to produce therapeutic proteins that are intended to impact disease.
Our current product candidates are designed to provide durable effects for patients with significant unmet medical needs and potentially changing the course of a disease and delivering improved patient outcomes. We are currently advancing and expanding an internal line of product candidates to address retinal neurodegenerative and metabolic diseases. These areas of focus have been strategically selected because we believe they can be uniquely addressed by our vectors, and within each focus area there are many diseases with significant unmet medical needs. Beyond our internal development programs, we selectively license components of our NAV Technology Platform, most typically single vectors for single indications to third-party companies whose vision and commitment to gene therapy is aligned with our own.
Before we review our recent progress, I'd like to take a moment to speak to what fundamentally motivates us, and that is our commitment to patients and their families. Since our Company's inception, this patient-focused mission remains our guide as we develop our own therapeutic programs to potentially treat patients with rare, serious and life threatening diseases. Our compassionate partnership with patients, their families and advocacy groups is at the center of what we do at REGENXBIO and we are inspired by the remarkable stories that motivate us to work harder and help save lives.
Our work and appreciation for the patient community is year-round, but February, Rare Disease Month, is an excellent opportunity to express our gratitude to them and raise awareness of the devastation of rare diseases. This past Friday, we held in all staff event at REGENXBIO in recognition of Rare Disease Day, tomorrow, February 28th, where we hosted patient advocacy groups including parents of children with rare diseases. The exchange was insightful and moving and it left us feeling deeply motivated. Two of the parents of children with rare diseases concluded their remarks to the Company with a quote from Dr. Martin Luther King, Jr., whatever you do, you have to keep moving forward, and we couldn't agree more.
We believe in the promise of our NAV technology gene therapy for rare diseases and are committed to continue working with rare disease community to address unmet needs and finding curative treatments. As you will see from our discussion today, we are moving our work forward in earnest.
I'd also like to take a moment to recognize the excellent work of our employees and the network of partners and clinical trial investigators, and of course, I want to acknowledge every patient and family who chooses to participate in our clinical trials, and the support networks that make this possible. We thank you for your engagement, commitment and trust in us.
And lastly, I'd be remiss if I didn't acknowledge the key opinion leaders who participated in our Analyst and Investor event last week, speaking to the landscape of wet age-related macular degeneration and retinal diseases. These retinal surgeons emphasize that vision loss from wet AMD is a serious public health concern among older adults and spoke to the potential role of a single treatment of RGX-314 to establish a new baseline of continuous anti-VEGF expression. And I want to extend my appreciation to doctors Pollack, Dugel, Heier and Ho for their insights and expertise. And a replay of the event can be found on our corporate website, www.regenxbio.com, and I'd encourage you to listen if you haven't already.
So now I'll turn and provide an update on our product candidates for retinal neurodegenerative metabolic diseases, and I'll begin with RGX-314 program for the treatment of wet AMD, a disease that affects more than 2 million patients in the US, Europe and Japan. It's been shown in multiple randomized controlled clinical trials that the majority of patients with wet AMD require frequent intravitreal anti-VEGF injections on a long-term basis to prevent vision loss. Inability to comply with the indicated treatment regimen of anti-VEGF injections in the real world setting due to an unsustainable treatment burden leads to loss of vision over time.
Now, RGX-314 utilizes the NAV AAV8 vector, which carries a gene encoding an anti-VEGF protein. The vector is introduced into the peripheral retinal cells via single subretinal injection, which has the potential to result in long-term continuous expression of the therapeutic protein. Subretinal delivery is a preferred route of administration because of the ability to achieve broader retinal coverage, higher protein expression, reduced sensitivity to neutralizing antibodies and demonstrated safety in multiple clinical trials. The expressed anti-VEGF antibody Fab neutralizes VEGF activity in a continuous fashion after a single administration, establishing a foundation of consistently expressed anti-VEGF therapy. The NAV AAV8 vector has been selected for this product candidate because it has demonstrated effective transduction of retinal cells and the ability to produce high levels of therapeutic proteins on a long-term basis in multiple preclinical animal models.
In January of this year, we reported that 24 subjects across four dose cohorts have been treated in the Phase 1 trial of RGX-314 and that RGX-314 continued to be well tolerated across all cohorts with no drug-related serious adverse events reported, drug related ocular inflammation or post-surgical inflammation beyond what is expected following a routine vitrectomy. Three of the six subjects in Cohort 3 continued to remain injection free at nine months, with persistent clinical durability of effect observed on best corrected visual acuity and central retinal thickness. Mean BCVA improved by 13 letters and mean CRT decreased by 37 microns from baseline in these subjects at nine months.
Additionally, RGX-314 intraocular protein expression was detected at one month in all of the subjects that had been dosed in Cohort 4 at that time, the 1.6 x 10^11 genome copies per eye dose. So mean protein levels were higher in Cohort 4 than previously reported in Cohort 3 at one month post RGX-314 administration as measured from aqueous samples by ECL assay.
Also last month, we announced that based on an amendment to the RGX-314 Phase 1 protocol filed with FDA, we were cleared to proceed to a Phase IIa trial under the current IND application, and this expansion is designed to further characterize RGX-314 treated subjects in a larger sample in order to enhance the design of an expected Phase IIb trial and accelerate the clinical development of RGX-314.
Today, we announced that we've completed dosing an additional six subjects for now a total of 12 subjects in Cohort 4 at that 1.6 x 10^11 genome copy per eye dose. So to date 30 subjects have been dosed in the recently expanded Phase IIa trial. We're currently recruiting an additional cohort of 12 patients, Cohort 5, at a dose of 2.5 x 10^11 genome copies per eye. We expect to present top line data from the Phase I-II clinical trial by the end of 2019. We remain on track to initiate a larger randomized controlled Phase IIb for wet AMD in late 2019. And we're also progressing toward filing a new IND for RGX-314 in the second half of 2019 for an additional Phase II clinical trial in another chronic retinal condition that responds to chronic anti-VEGF therapy.
Next, I'm going to turn to our programs for MPS I and MPS II, which are lysosomal storage disorders caused by defects in the IDS and IDUA genes. While approved and marketed enzyme replacement therapies do exist, they are indicated for the treatment of the non-neurological symptoms of MPS II and MPS I, but do not address the central nervous system symptoms, which are present in many patients affected by the disease. Our programs are designed to address this area of significant unmet need by utilizing the NAV AAV9 vector through a one-time administration into the cerebral spinal fluid via an intracisternal injection.
To summarize the updates for these programs for RGX-121 for the treatment of MPS II at the end of 2018, one subject has been dosed in the first of two expected dose cohorts in the Phase I-II clinical trial. At the eight week safety assessment, RGX-121 had been well tolerated with no serious adverse events reported as of December 4, 2018. Additional recruitment and site activation is ongoing, and we expect to present an interim data update from the Phase I-II clinical trial in the second half of this year. For RGX-111 for the treatment of MPS I, subject recruitment continues in the Phase I clinical trial. Under the current FDA protocol, recruitment is focused on an initial subject over 18 years of age. Enrollment in the clinical trial is anticipated to begin mid-2019.
Turning to our metabolic franchise. We are progressing RGX-501 for the treatment of homozygous familial hypercholesterolemia or HoFH. HoFH is a rare genetic disorder caused by mutations in the gene encoding the low density lipoprotein or LDL receptor. RGX-501 has the potential to address underlying genetic defect responsible for HoFH by correcting the LDL receptor deficiency. And in November 2018, we entered into a new clinical trial agreement with the University of Pennsylvania, the original RGX-501 trial sponsor, which allowed REGENXBIO to become the trial sponsor following required activities with regulatory authorities to effectuate the transfer of sponsorship. We believe this will allow for an enhanced visibility and control over the RGX-501 trial. The University of Pennsylvania will continue to remain an important research partner as we progress the trial.
We previously reported that a total of six subjects enrolled in two dose cohorts in the Phase I-II trial for RGX-501. All three subjects dosed at the 7.5 x 10^12 genome copies per kilogram of body weight dose, Cohort 2, experienced elevation in transaminases four to six weeks post dosing, were asymptomatic and responded rapidly to the initiation of corticosteroids followed by a slow taper, with normalization of the transaminases and no new drug related SAEs were reported as of December 31, 2018.
We submitted an amendment to the Phase I-II clinical trial protocol to the FDA to allow for enrollment of additional subjects at the Cohort 2 dose using corticosteroid prophylaxis, and patient recruitment has resumed. We expect to present interim data from Cohort 2 with corticosteroid prophylaxis from the Phase I/II clinical trial in the second half of 2019.
Lastly turning to RGX-181. This program aims to develop a one-time treatment to halt progression of the CLN2 form of Batten disease, one of the most common forms of Batten disease, a rare pediatric neurodegenerative condition. So this is part of our neurodegenerative franchise. We announced last month that we've initiated IND enabling studies. We expect to file an IND for a first in human clinical trial in the second half of 2019. You may recall that in November of 2018, we announced that the FDA had granted orphan drug designation for RGX-181. And just last month, we announced that the agency granted RGX-181 a rare pediatric disease designation.
So we'll continue our diligent work to drive these programs forward, and we look forward to providing you with more updates on our progress throughout the year.
Beyond our internal progress, the NAV Technology Platform also continues to advance through efforts of our licensed external partners. And as of December 31, 2018, our technology was being applied in more than 20 partnered product candidates in development by NAV Technology licensees. 14 of these partnered product candidates are in active clinical development and one partner product candidate has been submitted for a biologics application -- license application or BLA with approval with -- with the FDA. As a reminder, our NAV technology licensees are developing programs in a broad range of therapeutic areas and disease indications.
Over 100 subjects have been treated in clinical trials sponsored by NAV technology licensees. As licensee programs progress and achieve efficacy and safety milestones, we believe that they further validate the versatility of the NAV Technology Platform and provide additional data that collectively drive the advancement of the AAV gene therapy space.
The several recent program updates from our NAV technology licensees at Ultragenyx, Audentes, Rocket, Lysogene and Sarepta are highlighted in our press release today. Additionally, two of the active clinical stage programs are applying the NAV technology in treatments for hemophilia A and are under development by hemophilia industry leaders, Takeda and Bayer, both of whom activated their clinical programs in 2018.
And of course, a key up -- a key upcoming milestone for the NAV Technology Platform is the expected launch of Novartis' ZOLGENSMA for the treatment of SMA Type I. In January 2009, Novartis announced that the company is on track to launch ZOLGENSMA in the United States and Japan in the first half of 2019 and in Europe in the second half of 2019 for the treatment of spinal muscular atrophy Type I. ZOLGENSMA uses the NAV AAV9 vector. REGENXBIO is eligible to receive $80 million in potential future commercial milestone payments in addition to regulatory milestones and royalties on net sales of ZOLGENSMA.
So overall, 2018 was a pivotal year for REGENXBIO. Significant progress was made in advancing the NAV Technology Platform across 18 clinical stage programs, four of which are part of our internal pipeline. In addition, in November of 2018 we announced the kick-off for the development of a new facility in Rockville, Maryland. The new facility, which should be available to us by 2020, will provide us with over 132,000 square feet of space, including options for expansion. And this will enable us to continue to meet our needs for growth in talent and capabilities, including the potential to install our own cGMP production facility in order to support the development and launch of NAV technology based treatments.
Looking ahead, we believe we are well positioned for a transformative 2019 as we build on last year's achievements and broaden our NAV technology footprint.
With that, I'll turn the call over to Vit for a review of the financials.
Vit Vasista -- Senior Vice President & Chief Financial Officer
Thank you, Ken.
REGENXBIO ended the year on December 31st, 2018, with cash, cash equivalents and marketable securities totaling $470.6 million compared to $176.4 million as of December 31st, 2017. Cash, equivalents and marketable securities as of December 31st, 2018, include $180 million received in 2018 in connection with the amendment to our license agreement with AveXis for the development and commercialization of treatments for SMA, as well as $189.1 million of aggregate net proceeds from our follow-on public offering of common stock completed in August 2018.
Revenues were $40.8 million and $218.5 million for the three months and year ended December 31st, 2018, respectively compared to $2 million and $10.4 million for the same periods in 2017. The increases were primarily attributable to $176.1 million of revenue recognized in 2018 under our amended license agreement with AveXis for the development and commercialization of treatments for SMA, as well as $35.6 million of revenue recognized in the fourth quarter of 2018 under our license agreement with Abeona for the development and commercialization of treatments for various diseases. Due to the non-recurring license revenue recognized under these licenses in 2018, REGENXBIO currently expects 2019 revenues to be substantially lower than 2018 revenues.
Research and development expenses were $24.3 million and $83.9 million for the three months and year ended December 31st, 2018, respectively compared to $14.2 million and $57.2 million for the same periods in 2017. The increases were primarily attributable to personnel costs as a result of increased headcount, laboratory and facilities costs and expenses associated with conducting clinical trials and externally sourced manufacturing-related services.
General and administrative expenses were $11.1 million and $36.9 million for the three months and year ended December 31st, 2018, respectively compared to $4.8 million and $27.2 million for the same periods in 2017. The increases were primarily attributable to personnel costs as a result of increased headcount and professional fees for advisory and other services.
Net income was $4.3 million or $0.12 basic and $0.11 diluted net income per share for the three months ended December 31st, 2018, compared to a net loss of $16 million or $0.51 basic and diluted net loss per share for the same period in 2017. Net income was $99.9 million or $2.99 basic and $2.73 diluted net income per share for the year ended December 31st, 2018, compared to a net loss of $73.2 million or $2.45 basic and diluted net loss per share for the same period in 2017.
As of December 31st, 2018, we had 36.1 million common shares outstanding.
Based on its current operating plan and excluding any commercial revenue from Novartis' ZOLGENSMA subject to approval by regulatory authorities, REGENXBIO reiterates that it expects its balance in cash, cash equivalents and marketable securities to be between $330 million and $350 million as of December 31st, 2019, which will be used to support the continued development of its lead product candidate programs. Importantly, REGENXBIO anticipates adding commercial revenues from ZOLGENSMA to its existing base of partner revenue this year pending approval by regulatory authorities.
With that, I will turn the call back to Ken to provide final thoughts and review our upcoming 2019 milestones.
Ken Mills -- President and Chief Executive Officer
Thanks, Vit. As usual, that's very exciting and well done.
Summarize what we've discussed today. Our expanded Phase II trial for RGX-314 for the treatment of wet AMD is under way with dosing completed for Cohort 4 and recruitment ongoing for subjects for Cohort 5. We expect to present top line data from the Phase I-IIa clinical trial by the end of 2019 and are on track to initiate a Phase IIb study for wet AMD in late 2019. We continue to advance development of RGX-314 in additional chronic retinal conditions that respond to anti-VEGF therapy and are progressing toward a new IND for a Phase II trial in an additional retinal condition in the second half of 2019.
At the end of 2018, one subject had been dosed in the first of two expected dose cohorts in the Phase I-II clinical trial for RGX-121 for the treatment of MPS II, additional recruitment and site activation is ongoing and we expect to present interim data update from the Phase I-II clinical trial in the second half of 2019. Subject recruitment also continues in the Phase I clinical trial for RGX-111 for the treatment of MPS I. Enrollment in the clinical trial is anticipated in mid-2019.
For RGX-501 for the treatment of HoFH, we submitted to FDA amendment to the Phase I-II clinical trial protocol to allow for enrollment of additional subjects at the Cohort 2 dose using corticosteroid prophylaxis and subject recruitment has resumed. We expect to present interim data from the Cohort 2 with corticosteroid prophylaxis from the Phase I-II clinical trial in the second half of 2019. And for RGX-181 for the treatment of CLN2 disease, we've initiated the IND enabling studies and expect to file an IND in the second half of 2019.
So at REGENXBIO, our mission is and remains to improve lives through the curative potential of gene therapy based on our proprietary NAV Technology Platform. With our innovative science, inspired employees and partners and strong cash position, we feel well positioned to achieve future milestones as we advance therapies for patients with significant unmet medical needs.
And with that, I'll turn it back over to the operator and open the call for questions.
Questions and Answers:
Operator
(Operator Instructions) Our first question comes from Gena Wang with Barclays. Your line is now open.
Xiaobin Gao -- Barclays -- Analyst
Hey, this is actually Xiaobin dialing in for Gena. Thank you so much for taking our question. So maybe just start with ZOLGENSMA. So with the approval, can you help us understand or give us more granularity regarding the regulatory milestone and also the shared royalty rate? And then for the second question, I just want to get your view about your CLN2 program versus Spark program and also its currently approved therapy. Thank you so much.
Ken Mills -- President and Chief Executive Officer
Hey, Xiaobin, this is Ken. Thanks for the question. So with respect to the launch of the Novartis product, we will have expecting -- we will be expecting some single-digit million regulatory milestones based on approvals that will record I guess in the quarters that those events occur. Otherwise, the $80 million commercial milestone fee that we are referring to is achieved when aggregate sales of the product reach $1 billion, and that would be cumulative. So that also will be an event driven process. With respect to the CLN2 program, RGX-181 stands on top of the science and clinical implementation of the 111 and 121 programs where we're using our AAV9 vector with an intracisternal administration and a one-time treatment to repatriate gene function within the brain for patients with CLN2 disease. We think this is highly differentiated from existing therapy that requires obviously repeat dosing and administration of exogenous protein, and we're encouraged by the fact that as it is those exogenous protein products sold by others for the treatment of CLN2 seem to be showing clinically meaningful effect. We think that sets up very well for a gene therapy approach. With respect to other programs that are going on in the gene therapy space, we think that we have an advantage in terms of how we are executing right now and we're looking forward to getting this into the clinic as quickly as possible.
Xiaobin Gao -- Barclays -- Analyst
Got it. Thank you so much.
Ken Mills -- President and Chief Executive Officer
Thanks, Xiaobin.
Operator
Our next question comes from Ying Huang with Bank of America Merrill Lynch. Your line is now open.
Chen -- Bank of America Merrill Lynch -- Analyst
Hi, good afternoon. This is Chen (ph) on for Ying. Thank you for taking my questions. So my first question is regarding the MPS II program that you're going to update in second half. I'm just wondering whether you can tell us how many patients are in line there for treatments and what is the baseline characteristics out there for example regarding age or severity? In addition, what kind of -- how many patients or biomarker data or even neurological improvement data can be expected in the second half? And I have a follow-up.
Ken Mills -- President and Chief Executive Officer
Sure, Chen. Yeah. Thanks for the question about that. So as we mentioned, so we've only enrolled one patient in the trial so far. We're actively recruiting and looking to get an additional patient enrolled in the first dose cohort soon. The data report at the end of the year is certainly going to be dependent on patient enrollment and the time that patients have been enrolled in the trial. We will expect to achieve the cut-off date toward the end of the year and be looking to provide information including biomarker, clinical measures, including whatever we can collect about baseline, natural history as well as changes in things like cognition and behavior that are going to be measured in part of the secondary endpoints. The first part of this trial -- so we're hoping to achieve dose escalation to the second cohort this year and have data on -- at least early data on the second dose cohort as whether -- as well as a longer-term data set on the first dose cohort. But we'll update across the year as we progress without enrollment. In terms of the background of the patients -- certainly the inclusion criteria require an understanding of their disease and the background of natural history. I think we have an age range in terms of inclusion criteria that can go down to young infants and up to basically younger boys. This is an X-linked disorder. So that's also going to be dependent on enrollments in a case-by-case basis. But I expect that there will be a little bit of a spectrum there, depending on how we enroll.
Chen -- Bank of America Merrill Lynch -- Analyst
Okay, thanks. And I have a follow-up question on the HoFH program. I know you saw some immunogenicity in the earlier part of the study. Now you have the amendment into the particle. But can you remind us whether you have disclosed what is triggering this immunogenicity? Is it (inaudible) or is it the transgene protein? Thanks.
Ken Mills -- President and Chief Executive Officer
We haven't disclosed it. I don't think that we know for certain. I mean, I think our hypothesis is that it's certainly related to treatment. It's presenting itself at time points that I think are familiar to and similar to other transaminase elevations that people are seeing with AAV in intravenous administrations. And I don't know that we know for certain what the component is, sort of the disease background of the patients, the gene transfer or the gene vector itself. I suspect it's probably a blend of all of those three. But I think we are confident that the corticosteroid regimen that we are implementing like what others have mentioned even recently in hemophilia studies for instance or in other programs that people are using for IV administration of AAV is going to be a meaningful step toward abrogating those observations.
Chen -- Bank of America Merrill Lynch -- Analyst
Okay. Thank you very much.
Ken Mills -- President and Chief Executive Officer
Thanks.
Operator
Our next question comes from Gbola Amusa with Chardan. Your line is now open.
Gbola Amusa -- Chardan -- Analyst
Hi, thanks. It's Gbola Amusa at Chardan. Thanks for taking my call. So two questions. First, obviously we've seen a flurry of deal activity or business development activity in the AAV based gene therapy space, whether it's partnerships, acquisitions or equity stakes, and I was just wondering if you're willing to offer some ideas as to what's driving this theme. Why is it happening? And then secondly, you're going to have a decent amount of cash at the end of the year even if you exclude any contributions from ZOLGENSMA. So just wondering if you could update us on your strategic priorities for uses of cash, if, let's say you potentially might acquire some capabilities that are external to the organization currently. Let me resummarize that. What might you do with your cash if you use it for programs that we're not aware of yet?
Ken Mills -- President and Chief Executive Officer
Sure, Gbola. Thanks a lot for the questions. I think stepping back to the broader question about some of the activity that's been going on in the field with respect to business development, collaborations and even acquisitions, I think we predicted since we took REGENX public in 2015 that there was really going to be a lot of new emerging clinical data that we were encouraged by, much of it deriving from the use of the NAV Technology Platform as it entered the clinic, and we saw other of our partners sharing that data. I think that's really been a stimulant. I think it certainly started in 2017 and has continued in 2018. As I mentioned, we have four or five individual company updates as highlights to our NAV Technology Platform in our press release today. I think different types of companies are starting to understand the importance of gene therapy and how it fits into long-term growth plans and it's something that I know we and others in our space have seen for a long time and we're committed to for a very long time. And that sort of relates to your second question in terms of cash and priorities. You know us. I mean, we have an interest in broadening and deepening the platform and especially including the internal pipeline. Right now, we're focused on retina and neurodegeneration and different metabolic diseases, right now HoFH, but last two years, Olivier has continued to grow out the research and development engine here at REGENX. We identified Batten disease as the first program since we've been public as an additional program to the pipeline. There are certain other things that we're investing in in terms of organic programs intramurally that we're excited about. And yeah, we continue to look at opportunities for one plus one equals three from a collaboration, partnership and even acquisition perspective. And I think everyone knows, either through the exercise we went through with Dimension originally or otherwise -- we think we have great capabilities that can match up with a lot of different things that may be going on in this space. And that's how we've intended to build the Company and sustain it for a long time. So use of proceeds, use of cash, from revenues from ZOLGENSMA, from licensing that we've done, has always intended to sort of reinforce and support the growth, the broadening and deepening of the REGENX pipeline.
Gbola Amusa -- Chardan -- Analyst
Great. Thanks, Ken.
Ken Mills -- President and Chief Executive Officer
Thanks. Take care.
Operator
Our next question comes from Ren Benjamin with Raymond James. Your line is now open.
Reni Benjamin -- Raymond James -- Analyst
Hey, good afternoon, guys. Thanks for taking the questions. Just a couple, maybe starting off with 314. You talk about the top line data by the end of 2019, Ken. Does that mean that we should be expecting both Cohort 4 and 5 data to be released around the same time? Because just my backwards or back of the envelope math would suggest July or August for Cohort 4 six month data.
Ken Mills -- President and Chief Executive Officer
Yeah, Ren, we're thinking about everything at once at this point. I don't think that -- because it all is going to affect the thinking that's going into the trial design and the dose selection for the Phase IIb. And so we see all of those things lining up as we complete that work. And we'll share it with everyone. So what we're aiming to do is get -- like we did last year when we reported updates on cohorts 1, 2 and 3 is, got all patients. So this would include Cohort 5 out to six months in order to be able to provide that comprehensive update.
Reni Benjamin -- Raymond James -- Analyst
Got it. And then the Phase IIb study, can you -- I don't know if you've mentioned it before, but can you give us a little bit of a sense as to what that study is going to look like when you initiate it in the -- in late 2019 in terms of size and what you're looking for?
Ken Mills -- President and Chief Executive Officer
Not too much more of a sense than what I said on the call today, which is -- it's going to be larger. It's going to be controlled. And we're certainly going to be focusing on endpoints that are less about safety and more about things that support distinguishing treatment effect, especially as it relates to visual acuity associated with RGX-314 against those control arm population. So part of the decision that's going to go into the size is going to be the data that we see over the course of the year as we continue to follow Cohort 3 and now Cohort 4 and Cohort 5 patients. But we'll be -- we'll be able to update on all that in detail in the second half of the year.
Reni Benjamin -- Raymond James -- Analyst
Okay. And then just my last question on the eye, and then I have a follow-up is, you're going to be filing an IND for another indication. I think in the Analyst Day you mentioned four other indications, non-proliferative diabetic nephropathy, proliferative diabetic nephropathy, retinal vein occlusion and diabetic macular edema. Is it fair to say that the IND will be one of those four indications or will it be something else entirely?
Ken Mills -- President and Chief Executive Officer
It's fair to say.
Reni Benjamin -- Raymond James -- Analyst
Got it. Okay.
Ken Mills -- President and Chief Executive Officer
I mean, I think -- I would emphasize, Ren, that we're choosing and I think interested in filing an IND for a Phase II trial for one of those indications now, but we are interested in all of those indications. So I think the work that we have going on I would emphasize is about development of the application of RGX-314 in the entirety of the spectrum of where it will make sense and we think at least this year we want to file an IND in an additional indication.
Reni Benjamin -- Raymond James -- Analyst
Got it, OK. Thanks for that clarification. And then just -- there was the acquisition today of Myonexus by Sarepta and they have the AAVrh74. I know one of the many patent states that you have is for AAVrh10. Can you talk a little bit about the difference between rh10 versus rh74 and what you see there?
Ken Mills -- President and Chief Executive Officer
Sorry, what do you mean differences?
Reni Benjamin -- Raymond James -- Analyst
So I'm just -- outside of the nomenclature, how different are the two vectors? Are they drastically different in terms of sequence homology or protein homology?
Ken Mills -- President and Chief Executive Officer
I think that what we have characterized previously is that the sequence identity of rh10 and the vector known as rh74 are quite similar. I think in fact over 98%, maybe on the order of 99% identical in terms of amino acid sequence. So I think that characterization is one thing, Ren. I would say that notwithstanding that fact, changes to amino acid sequences in vectors biologically change other characteristics of how the vectors function very differently. So I think in the case -- rh74, the vector known as, and rh10 are not the same vector biologically but their sequence -- and their characterization of their sequence by amino acid analysis is very similar. And that's kind of -- we know that because we study that because at REGENX, we have all of these capsids that have been discovered, amino acid analyzed, sequence analyzed and patents filed on and we focus very much often on the sequence space that is plus or minus 5%, sometimes even plus or minus 10% of capsid identity from an intellectual property perspective, but also to understand biologically what's different. So we have sequence claims covering the rh10 capsid sequence that go beyond its literal sequence, so things like plus or minus 5% of that sequence doesn't mean that those other vectors are identical to our rh10. It just means that their sequences are identical.
Reni Benjamin -- Raymond James -- Analyst
Got it. Okay. Thanks for the clarification. Just one final question regarding the steroid regimen for HoFH, the HoFH indication. Can you just talk a little bit about was there -- is it pretty standard when the steroids are prophylactically administered? Is there any delay (ph) between kind of what -- when you can administer? How many weeks after the virus has been administered? How are you guys thinking about that going forward?
Ken Mills -- President and Chief Executive Officer
I mean, I think across the field, we've seen variations on a theme. But I think there's been a pretty standard and sort of normal implementation, and I think we've gotten input from folks in our partner universe and other physicians who've been involved at sites in AAV studies for input, and I think we're -- my view, we're sort of down the middle of the stairway, the way that most people are with that approach.
Reni Benjamin -- Raymond James -- Analyst
Got it. Thanks very much.
Ken Mills -- President and Chief Executive Officer
Sure.
Operator
And our next question comes from Mani Foroohar with Leerink. Your lines now open.
Mani Foroohar -- Leerink Partners -- Analyst
Hey, guys. Thanks for taking my question on a busy and really informative event. It was really helpful here in New York, great for us that are New York based in particular. (inaudible) about the HoFH program, when you think about the appropriate steroid dose to avoid a T-cell response et cetera, like how do you think about what the right dose is? I mean, what's your strategy? And then I have a couple follow-ups.
Ken Mills -- President and Chief Executive Officer
Again, I don't know that we're dosing in response to a T-cell response, Mani, specifically. Again, like as I alluded to with Chen's question, I mean, I think -- we've got a broad spectrum understanding here of things that may be affecting some of the clinical observations we're having, and I think we're borrowing from observations that others have had that are similar. I would not say that we think that we're treating any one sort of specific phenomenon here. And so -- again, that's what is driving our approach right now for these corticosteroid regimens, including in HoFH, and I think that -- I don't know if it's active and up on the trial database right now, but we can follow up with people as to what exactly the protocol regimen is going to be or will in the near future just to make that more clear. But I think that some -- it's something that in my view is very consistent with what others have done with IV administration of all different types of AAVs, not just like our AAV8 vector that we're using in HoFH.
Mani Foroohar -- Leerink Partners -- Analyst
Great. And on the wet AMD, your study today to my knowledge have been in patients who are non-anti-VEGF responders or anti-VEGF experience, Lucentis, Eylea, et cetera, should we expect all -- all the -- all participants in your future studies, controlled or otherwise, to be anti-VEGF responders as well, and if so, how do you define an anti-VEGF responder?
Ken Mills -- President and Chief Executive Officer
Yeah, so I guess the first part of your question is -- no, I think as the program expands over time, including into other retinal responsive indications to VEGF therapy, we'll be looking for sort of earlier diagnosis in even patients who potentially might be naive to anti-VEGF therapy although that's more of a challenge these days, given the sort of spectrum of standard of care that's available, especially in the US. And with respect to how we consider and how we sort of characterize VEGF response, I think that's -- we refer to that based on engagement with the community and in terms of how we've applied our inclusion criteria and it often has been, in this particular trial, it was really a function of looking at the trailing eight months and being confident that there had been not only a diagnosis, but there had been regular administration of an existing treatment either Avastin, Lucentis or Eylea. When you go through that exercise, what you find is most of those patients, and I think like we've reported on average for the trial, many of those patients have actually been on treatment for years. And I think so that more than reinforces kind of their responsiveness. But the minimum requirement in the case of the trial design that we put together for the Phase I and now IIa was a minimum of four -- diagnosis and then four injections in the preceding eight months coming into the trial. I think that we may make some changes to that. There may be some stratification to it again. I think as the program expands, we're interested to learn more about what RGX-314 is doing across what we know is millions of patients so therefore naturally a heterogeneous population so that we can continue to sort of work with the investigators and do our own work to figure out how it can be best used.
Mani Foroohar -- Leerink Partners -- Analyst
Great, that's very helpful. I'm going to hop back into the queue to let my colleagues if they want a chance for some questions.
Ken Mills -- President and Chief Executive Officer
Queue is done, Mani, if you got another one.
Mani Foroohar -- Leerink Partners -- Analyst
All right. I do have another one. Great. The only other question -- the other one I have is on manufacturing. So obviously, you're giving relatively low doses per patient per organ for ophthalmological indications even though it's a larger population versus systemic or CNS wide administration. How do you think of what should be manufactured in-house on a commercial stage? And what's more appropriate for a CMO relationship? And I guess how is your -- how is your manufacturing strategy by indication? How do you think about it?
Ken Mills -- President and Chief Executive Officer
Yeah, it's a great question. I think you're right because I think we're among -- among the companies out there, a pretty broad spectrum. Even though our HoFH program right now, the Cohort 2 dose is only 5e12 (ph). I mean, that's still much higher per kg, that is, of course, in an adult. It's much more than what's required on a per eye basis or even in the CNS indications. So I think we right now have a pretty good sense that we have the systems in place and can bring sort of scale online to support what we would say would be sort of middle to low dose sort of metabolic intravenous type of administrations -- route of administration-wise and that -- so that -- that would provide coverage for our CNS indications and any ocular indication. As you start to get into higher dose intravenous administration, whether you're targeting skeletal muscle or different myocytes including skeletal muscle or you just need more in order to drive certain levels of expression through some of the liver-directed gene therapy. It does -- it requires a different physical plan. So it can take you from 500 liter scale in a bioreactor up to like 2,000, and I would say in terms of our planning and our thinking about like the new facility that we're building out couple of doors down here for move-in in 2020, we think that we will have capacity internally and the availability for it if needed at that 500 liter scale, and that's where we're focused right now. If we had to go much beyond that we would be sort of looking at sort of sharing in some of the CMO infrastructure that's out there as you get up north of that.
Mani Foroohar -- Leerink Partners -- Analyst
Great. Thank you.
Ken Mills -- President and Chief Executive Officer
Okay. Thanks a lot for the questions.
Operator, I think we're done.
Operator
At this time, I'm showing no further questions. I'd like to turn the call back over for any closing remarks.
Ken Mills -- President and Chief Executive Officer
Thank you. And thank you, everyone, for joining us today. We are working to realize many significant achievements in 2019, and we're looking forward to providing more updates as the year goes on. Have a great night. And we'll see everyone soon.
Operator
Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program. You may now disconnect. Everyone, have a great day.
Duration: 51 minutes
Call participants:
Patrick J. Christmas -- Senior Vice President & General Counsel
Ken Mills -- President and Chief Executive Officer
Vit Vasista -- Senior Vice President & Chief Financial Officer
Xiaobin Gao -- Barclays -- Analyst
Chen -- Bank of America Merrill Lynch -- Analyst
Gbola Amusa -- Chardan -- Analyst
Reni Benjamin -- Raymond James -- Analyst
Mani Foroohar -- Leerink Partners -- Analyst
Transcript powered by AlphaStreet
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
More From The Motley Fool
Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
